figure
posted on 2025-11-13, 11:00 authored by Anil Abraham Joy, Nicholas Cheng, Karen A. Gelmon, Mihaela Mates, Christine Desbiens, Mark Clemons, Sara Taylor, Julie Lemieux, Angela DeLuca, Louis Gasparini, Ilinca Lungu, David Soave, Alex Fortuna, Trevor Pugh, Shuo Shuo Liu, John M.S. Bartlett, Philip Awadalla, Melanie Spears, Bingshu E. Chen, Jane Bayani, Wendy R. Parulekar <p>Somatic variants detected in cfDNA associated with PFS time at baseline and first follow-up at week 12. <b>A</b> and <b>B,</b> Summary of genetic variants captured at (<b>A</b>) baseline prior to palbociclib treatment and at (<b>B</b>) week 12. Blue squares indicate the detection of a somatic variant in cfDNA for individuals. Barplot colors indicate variant classification. <b>C</b> and <b>D,</b> HR associated with PFS time for genetic variants detected at (<b>C</b>) baseline and at (<b>D</b>) week 12. Red points indicate gene variants significantly associated with PFS. <b>E–I,</b> Kaplan–Meier curves of mutations significantly associated with poor PFS time at (<b>E–G</b>) baseline in (<b>E</b>) <i>SETD2</i>, (<b>F</b>) <i>DDR2</i>, and (<b>G</b>) <i>FGFR4</i> and (<b>H</b> and <b>I</b>) at week 12 in (<b>H</b>) <i>TP53</i> and (<b>I</b>) <i>ESR1</i>. <b>J</b> and <b>K,</b> Kaplan–Meier curves of mutations associated with poor PFS in groups of genes in the (<b>J</b>) DNA repair pathway and (<b>K</b>) MAPK cascade.</p>
Funding
Pfizer Canada (Pfizer Canada Inc.)
Canadian Cancer Society (CCS)
History
ARTICLE ABSTRACT
The randomized phase II MA.38 trial estimated the relative progression-free survival (PFS) associated with second-line endocrine therapy plus palbociclib administered on a 100 mg continuous daily dosing (CDD) schedule compared with the standard dose schedule (SDS) of 125 mg (days 1–21 of a 28-day cycle). A total of 180 patients were allocated 1:1 to protocol therapy. Molecular profiling was performed on the archival tissue and cell-free DNA (cfDNA) at enrollment, 3 months, and 6 months. The primary analysis for PFS demonstrated a similar outcome for the CDD versus SDS treatment strategy: HR = 0.93 (90% confidence interval, 0.66–1.30). Secondary efficacy measures for CDD versus SDS included the following: overall survival, HR = 1.07 (90% confidence interval, 0.67–1.69); response rate, 16.1% versus 18.0% (P = 0.66); median duration of response, 4.2 months (range, 2.8–13.9 months) versus 5.6 months (range, 2.4–13.9 months; P = 0.86); and clinical benefit rate, 53.2% versus 57.3% (P = 0.89). cfDNA profiling of the baseline enrollment sample prior to palbociclib commencement showed low tumor fraction (HR = 2.28; P = 9.9 × 10−6); higher short/long fragment length ratios (HR = 1.19; P = 0.049) and cfDNA variants in FGFR4 (HR = 3.65; P = 0.012) were prognostic and associated with inferior PFS. Variants in TP53 (HR = 2.48; P = 0.006) and ESR1 (HR = 3.42; P = 0.005) detected at 12 weeks on treatment were also associated with poor PFS. CDD palbociclib 100 mg dosing was not associated with improved efficacy compared with the standard intermittent 125 mg dosing schedule. Additionally, we identified prognostic biomarkers in alignment with prior research and demonstrated the value of cfDNA dynamics, including fragment length ratios and tumor fraction as a measure of treatment response.
A continuous 100 mg dosing schedule of palbociclib was tolerable but not associated with improved efficacy signals versus the standard intermittent 125 mg (days 1–21 of a 28-day cycle) schedule. Mutations detected in liquid biopsies and changes in cfDNA dynamics were linked to poor outcomes and may identify patients with treatment-resistant cancer.
